Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2005
05/26/2005US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample
05/26/2005US20050113370 Therapeutic substituted indazole derivatives
05/26/2005US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic
05/26/2005US20050113362 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders
05/26/2005US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries
05/26/2005US20050113321 DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor
05/26/2005US20050113315 Such as methyl-4-(2-hydroxybenzyl)benzoate for treatment/prevention of diabetes, diabetic complications, and/or obesity; sodium glucose transport protein inhibitors
05/26/2005US20050113312 2-0-(-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containning compositions comprising it
05/26/2005US20050113308 Pentapetide containing a proline amino acid; cytotoxic agent
05/26/2005US20050113304 Recombinant expression system for production of a peptide capable of inhibiting the protease activity of Botulinum toxin B or tetanus toxin which expression system comprises a nucleotide sequence encoding the peptide operably linked to a control sequence for effecting expression
05/26/2005US20050113301 Administering calcitonin and dehydroepiandrosterone (DHEA) to patient being treated for systemic lupus erythematosus where the immunosuppressant tends to reduce bone mineral density(BMD); osteoporosis
05/26/2005US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis
05/26/2005US20050113289 Conjugate of hemoglobin covalently joined to a polysaccharide; for use as synthetic blood; preventing hemorrhagic shock
05/26/2005US20050113284 Drug for regenerating tissue and vessel and method therefor
05/26/2005US20050112748 Low molecular weight gtpase rhot
05/26/2005US20050112721 Chimeric peptide immunogens
05/26/2005US20050112709 Histone h3methyltransferase polypeptide
05/26/2005US20050112681 Isolated human transporter proteins, nucleic acid molecules encoding human, transporter proteins, and uses thereof
05/26/2005US20050112596 APRIL-A novel protein with growth effect
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112565 Proteases
05/26/2005US20050112563 Sub-sequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme; diagnostics; antisense therapeutics
05/26/2005US20050112206 Mixture of drug, aminoacrylate polymer and acid
05/26/2005US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics
05/26/2005US20050112150 Promoting exfoliation; mixture of polypeptide and protease; skin disorders; antitumor agents
05/26/2005US20050112127 Treating with active material having heavy chain variable region of amino acid sequence 7 and light chain variable region of sequence 8; psoriasis, multiple sclerosis, Crohn's disease
05/26/2005US20050112120 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
05/26/2005US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators
05/26/2005US20050112069 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
05/26/2005US20050112060 Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
05/26/2005CA2545435A1 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005CA2545433A1 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005CA2545384A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
05/25/2005EP1533382A1 Beta glucan-containing fat and oil compositions and novel microorganism capable of producing beta-glucan
05/25/2005EP1533374A1 Novel peptides having camp producing activity
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1533313A1 Novel derivative of flavone c-glycoside and composition containing the same
05/25/2005EP1533312A1 Hetero-bicyclic compounds
05/25/2005EP1533304A1 Amide derivative
05/25/2005EP1533299A1 Indole derivatives and drugs containing the same
05/25/2005EP1533294A1 Beta-alanine derivative and use thereof
05/25/2005EP1533292A1 Dibenzylamine compound and medicinal use thereof
05/25/2005EP1532987A1 Agents for gene therapeutic for cerebrovascular disorders
05/25/2005EP1532986A2 Pharmaceutical composition for treatment of rhinitis
05/25/2005EP1532985A1 Process for producing sustained-release composition
05/25/2005EP1532979A1 Drug composition for blood sugar control
05/25/2005EP1532978A1 Remedy for urinary frequency and urinary incontinence
05/25/2005EP1532434A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
05/25/2005EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use
05/25/2005EP1532250A1 Fcyriia transgenic animal model for autoimmune disease
05/25/2005EP1532242A2 Methods for preparing purified prostaglandin e synthase
05/25/2005EP1532174A2 Anti-igf-i receptor antibody
05/25/2005EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3
05/25/2005EP1532138A1 Inhibitors of tyrosine kinases
05/25/2005EP1532135A1 Nf-kb inhibitors
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532130A1 Process for the production of an immunosuppressant
05/25/2005EP1532124A1 Novel compounds
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532109A1 Pyrrolidine derivatives as oxytocin antagonists
05/25/2005EP1532105A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof
05/25/2005EP1531906A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531874A1 Embolization
05/25/2005EP1531873A2 Agent delivery particle
05/25/2005EP1531863A2 Antibody-avidin fusion proteins as cytotoxic drugs
05/25/2005EP1531857A1 Metalloproteinase inhibitors
05/25/2005EP1531855A2 Treatment of bone disorders with skeletal anabolic drugs
05/25/2005EP1531847A2 Pharmaceutical formulation
05/25/2005EP1531844A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
05/25/2005EP1531842A2 Regulation of cell growth by muc1
05/25/2005EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
05/25/2005EP1531824A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531815A1 Glucokinase activators
05/25/2005EP1531814A1 Sustained-release tablet composition of pramipexole
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
05/25/2005EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
05/25/2005EP1531793A1 Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
05/25/2005EP1531791A2 Prevention and reduction of blood loss
05/25/2005EP1531716A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
05/25/2005EP1531684A1 Method for controlling hairballs
05/25/2005EP1531676A2 Compositions and methods for liver growth and liver protection
05/25/2005EP1442016A4 1h-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
05/25/2005EP1365762A4 Method for increasing leptin levels using nicotinic acid compounds
05/25/2005EP1341791B1 Thioether substituted imidazoquinolines
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1282592B1 Use of amines
05/25/2005EP1279039A4 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
05/25/2005EP1259231B1 Naphthoquinone derivatives as cd45 inhibitors
05/25/2005EP1213287B1 Substituted benzylthiazolidine-2,4-dione derivatives
05/25/2005EP1207158B1 Substituted benzylthiazolidine-2,4-dione derivatives
05/25/2005EP1165615B1 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE
1 ... 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 ... 1564